Embecta Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1B-9.3% YoYTTM through 30 Jun 2026
Net Income $87.5M+11.7% YoYTTM through 30 Jun 2026
Free Cash Flow $164.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 57.6% |
| EBITDA Margin | 26.3% |
| Operating Margin | 15.8% |
| Net Margin | 8.6% |
Returns
-14.3%ROE
16.8%ROA
Balance Sheet Health
Debt / Equity-2.14x
Current Ratio1.18x
Net Debt$1.2B
Cash & Equivalents$214.7M
Quality Metrics
Altman Z-Score1.31
Piotroski F-Score3 / 9
FCF Margin16.2%
Rule of 4016.4
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $1.1B
Diluted EPS$1.47TTMFY2025: $1.62
Dividend
$0.16Per share, FY202614.81%Yield
Capital Allocation
R&D Spend$20.2M
Capex Intensity0.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Pen Needles | $784M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.